The effects of gastric bypass surgery on drug absorption and pharmacokinetics

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 12, 2012, Pages 1505-1519

  Brocks, Dion R ^a   Ben Eltriki, Mohamed ^a   Gabr, Raniah Q ^a   Padwal, Raj S ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Bariatric surgery; Bioavailability; Cardiometabolic syndrome; Drug disposition; Obesity; Pharmacokinetics; Roux en Y gastric bypass

Indexed keywords

ATORVASTATIN; AZITHROMYCIN; BILE SALT; BISPHOSPHONIC ACID DERIVATIVE; METFORMIN; MOXIFLOXACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOBARBITAL; PHENYTOIN; RAPAMYCIN; SALICYLIC ACID; SERTRALINE; TACROLIMUS; TAMOXIFEN;

BODY MASS; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG TRANSPORT; FUNCTIONAL ANATOMY; GASTROINTESTINAL ABSORPTION; HUMAN; OBESITY; REVIEW; ROUX Y ANASTOMOSIS; STOMACH BYPASS; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ANASTOMOSIS, ROUX-EN-Y; BIOLOGICAL AVAILABILITY; GASTRIC BYPASS; HUMANS; OBESITY, MORBID; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PROTEINS; WEIGHT LOSS;

EID: 84869384740     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.722757     Document Type: Review

References (112)

1. Haslam DW, James WP. Obesity. Lancet 2005;366(9492):1197-209
2. Caballero B. The global epidemic of obesity: an overview. Epidemiol Rev 2007;29:1-5
3. Morrish GA, Pai MP, Green B. The effects of obesity on drug pharmacokinetics in humans. Expert Opin Drug Metab Toxicol 2011;7(6):697-706
4. Shields M, Carroll MD, Ogden CL. Adult obesity prevalence in Canada and the United States. NCHS Data Brief 2011;56:1-8
5. Anonymous. Obesity and overweight. Fact Sheet 311. In: Organization WH, editor. World health organization. edition. World Health Organization; Geneva:2006
6. Vincent HK, Heywood K, Connelly J, Hurley RW. Obesity and weight loss in the treatment and prevention of osteoarthritis. PM R 2012;4(5 Suppl):S59-67
7. Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009;373(9669):1083-96
8. Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight and obesity. JAMA 1999;282(16):1523-9
9. Peeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med 2003;138(1):24-32
10. Jain R, Chung SM, Jain L, et al. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther 2011;90(1):77-89
11. Maury E, Ehala-Aleksejev K, Guiot Y, et al. Adipokines oversecreted by omental adipose tissue in human obesity. American journal of physiology Endocrinology and metabolism 2007;293(3):E656-65
12. Lago F, Gomez R, Conde J, et al. Cardiometabolic comorbidities and rheumatic diseases: focus on the role of fat mass and adipokines. Arthritis Care Res 2011;63(8):1083-90
13. Gibbs H, Broom J, Brown J, et al. The impact of obesity on drug prescribing in primary care. Br J Gen Pract 2005; 55(519):743-9
14. Lau DC, Douketis JD, Morrison KM, et al. Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ 2006;176(8):S1-13
15. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292(14):1724-37
16. Strychar I. Diet in the management of weight loss. CMAJ 2006;174(1):56-63
17. Shick SM, Wing RR, Klem ML, et al. Persons successful at long-term weight loss and maintenance continue to consume a low-energy, low-fat diet. J Am Diet Assoc 1998;98(4):408-13
18. Tate DF, Jeffery RW, Sherwood NE, Wing RR. Long-term weight losses associated with prescription of higher physical activity goals. Are higher levels of physical activity protective against weight regain? Am J Clin Nutrit 2007;85(4):954-9
19. Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007;335(7631):1194-9
20. Neels JG, Olefsky JM. Inflamed fat: what starts the fire? J Clin Invest 2006;116(1):33-5
21. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112(12):1796-808
22. Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008;34(1):2-11
23. Kalitsky-Szirtes J, Shayeganpour A, Brocks DR, Piquette-Miller M. Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats. Drug Metab Dispos 2004;32(1):20-7
24. Piquette-Miller M, Pak A, Kim H, et al. Decreased expression and activity of P-glycoprotein in rat liver during acute inflammation. Pharm Res 1998;15(5):706-11
25. Vee ML, Lecureur V, Stieger B, Fardel O. Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6. Drug Metab Dispos 2009;37(3):685-93
26. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000;39(3):215-31
27. Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004;58(2):119-33
28. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010;49(2):71-87
29. Flechner SM, Kolbeinsson ME, Tam J, Lum B. The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients. Transplantation 1989;47(5):806-10
30. Cheymol G, Weissenburger J, Poirier JM, Gellee C. The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. Br J Clin Pharmacol 1995;39(6):684-7
31. Greenblatt DJ, Abernethy DR, Locniskar A, et al. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 1984;61(1):27-35
32. Bowman SL, Hudson SA, Simpson G, et al. A comparison of the pharmacokinetics of propranolol in obese and normal volunteers. Br J Clin Pharmacol 1986;21(5):529-32
33. Edelman AB, Cherala G, Stanczyk FZ. Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review. Contraception 2010;82(4):314-23
34. Sanderink GJ, Le Liboux A, Jariwala N, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 2002;72(3):308-18
35. Clauson PG, Linde B. Absorption of rapid-acting insulin in obese and nonobese NIDDM patients. Diabetes Care 1995;18(7):986-91
36. Jang EH, Kim HK, Park CS, Kang JH. Increased expression of hepatic organic cation transporter 1 and hepatic distribution of metformin in high-fat diet-induced obese mice. Drug Metab Pharmacokinet 2010;25(4):392-7
37. Paxton JW, Briant RH. Alpha 1-acid glycoprotein concentrations and propranolol binding in elderly patients with acute illness. Br J Clin Pharmacol 1984;18(5):806-10
38. Patel JP, Brocks DR. The effect of oral lipids and circulating lipoproteins on the metabolism of drugs. Expert Opin Drug Metab Toxicol 2009;5(11):1385-98
39. Varady KA, Lamarche B, Santosa S, et al. Effect of weight loss resulting from a combined low-fat diet/exercise regimen on low-density lipoprotein particle size and distribution in obese women. Metabolism 2006;55(10):1302-7
40. Caraco Y, Zylber-Katz E, Berry EM, Levy M. Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism. Eur J Clin Pharmacol 1995;47(6):525-30
41. Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci 1999;88(1):1-7
42. Emery MG, Fisher JM, Chien JY, et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 2003;38(2):428-35
43. Kotlyar M, Carson SW. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther 1999;37(1):8-19
44. Abernethy DR, Greenblatt DJ, Divoll M, Shader RI. Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen. J Lab Clin Med 1983;101(6):873-80
45. Abernethy DR, Divoll M, Greenblatt DJ, Ameer B. Obesity, sex, and acetaminophen disposition. Clin Pharmacol Ther 1982;31(6):783-90
46. Naumnik B, Mysliwiec M. Renal consequences of obesity. Med Sci Monit 2010;16(8):RA163-70
47. Wurtz R, Itokazu G, Rodvold K. Antimicrobial dosing in obese patients. Clin Infect Dis 1997;25(1):112-18
48. Salazar DE, Corcoran GB. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med 1988;84(6):1053-60
49. Henegar JR, Bigler SA, Henegar LK, et al. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001;12(6):1211-17
50. Anastasio P, Spitali L, Frangiosa A, et al. Glomerular filtration rate in severely overweight normotensive humans. Am J Kidney Dis 2000;35(6):1144-8
51. Janmahasatian S, Duffull SB, Chagnac A, et al. Lean body mass normalizes the effect of obesity on renal function. Br J Clin Pharmacol 2008;65(6):964-5
52. Cherrington NJ, Slitt AL, Li N, Klaassen CD. Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats. Drug Metab Dispos 2004;32(7):734-41
53. Varma MV, Rotter CJ, Chupka J, et al. pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm 2011;8(4):1303-13
54. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009;158(3):693-705
55. Hamad GG, Helsel JC, Perel JM, et al. The effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors. Am J Psychiatry 2012;169:3:256-63
56. Padwal R, Klarenbach S, Wiebe N, et al. Bariatric surgery: a systematic review of the clinical and economic evidence. J Gen Intern Med 2011;26(10):1183-94
57. Elder KA, Wolfe BM. Bariatric surgery: a review of procedures and outcomes. Gastroenterology 2007;132(6):2253-71
58. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009;122(3):248-56; e245
59. Sugerman HJ, Wolfe LG, Sica DA, Clore JN. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg 2003;237(6):751-6; discussion 757-758
60. Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev 2010;11(1):41-50
61. Buchwald H, Oien DM. Metabolic/bariatric surgery Worldwide. 2008;Obes Surg 2009;19(12):1605-11
62. Chand B, Gugliotti D, Schauer P, Steckner K. Perioperative management of the bariatric surgery patient: focus on cardiac and anesthesia considerations. Cleve Clin J Med 2006;73(Suppl 1):S51-6
63. Edwards A, Ensom MH. Pharmacokinetic effects of bariatric surgery. Ann Pharmacother 2012;46(1):130-6
64. Samuel I, Mason EE, Renquist KE, et al. Bariatric surgery trends: an 18-year report from the International Bariatric Surgery Registry. Am J Surg 2006;192(5):657-62
65. Eldar S, Heneghan HM, Brethauer SA, Schauer PR. Bariatric surgery for treatment of obesity. Int J Obes (Lond) 2011;35(Suppl 3):S16-21
66. Schernthaner G, Brix JM, Kopp HP, Schernthaner GH. Cure of type 2 diabetes by metabolic surgery? A critical analysis of the evidence in 2010. Diabetes Care 2011;34(Suppl 2):S355-60
67. Christou N, Efthimiou E. Five-year outcomes of laparoscopic adjustable gastric banding and laparoscopic Roux-en-Y gastric bypass in a comprehensive bariatric surgery program in Canada. Can J Surg 2009;52(6):E249-58
68. Miller AD, Smith KM. Medication and nutrient administration considerations after bariatric surgery. Am J Health Syst Pharm 2006;63(19):1852-7
69. Bjorneklett A, Viddal KO, Midtvedt T, Nygaard K. Intestinal and gastric bypass. Changes in intestinal microecology after surgical treatment of morbid obesity in man. Scand J Gastroenterol 1981;16(5):681-7
70. Gubbins PO, Bertch KE. Drug absorption in gastrointestinal disease and surgery. Clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet 1991;21(6):431-47
71. Darwich AS, Henderson K, Burgin A, et al. Trends in oral drug bioavailability following bariatric surgery: Examining the variable extent of impact on exposure of different drug classes. Br J Clin Pharmacol 2012
72. Akkary E, Sidani S, Boonsiri J, et al. The paradox of the pouch: prompt emptying predicts improved weight loss after laparoscopic Roux-Y gastric bypass. Surg Endosc 2009;23(4):790-4
73. Hogben CA, Schanker LS, Tocco DJ, Brodie BB. Absorption of drugs from the stomach. II. The human. J Pharmacol Exp Ther 1957;120(4):540-5
74. Seaman JS, Bowers SP, Dixon P, Schindler L. Dissolution of common psychiatric medications in a Roux-en-Y gastric bypass model. Psychosomatics 2005;46(3):250-3
75. Malone M. Altered drug disposition in obesity and after bariatric surgery. Nutrit Clin Pract 2003;18(2):131-5
76. Smith A, Henriksen B, Cohen A. Pharmacokinetic considerations in Roux-en-Y gastric bypass patients. Am J Health Syst Pharm 2011;68(23):2241-7
77. Kim MS, Wang S, Shen Z, et al. Differences in the pharmacokinetics of peroxisome proliferator-activated receptor agonists in genetically obese Zucker and sprague-dawley rats: implications of decreased glucuronidation in obese Zucker rats. Drug Metab Dispos 2004;32(9):909-14
78. Patel JP, Hamdy DA, El-Kadi AO, Brocks DR. Effect of Serum Lipoproteins on Stereoselective Halofantrine Metabolism by Rat Hepatocytes. Chirality 2012;24(7):558-65
79. Shayeganpour A, Korashy H, Patel JP, et al. The impact of experimental hyperlipidemia on the distribution and metabolism of amiodarone in rat. Int J Pharm 2008;361(1-2):78-86
80. Shedlofsky SI, Israel BC, McClain CJ, et al. Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J Clin Invest 1994;94(6):2209-14
81. Miller GD, Nicklas BJ, Fernandez A. Serial changes in inflammatory biomarkers after Roux-en-Y gastric bypass surgery. Surg Obes Relat Dis 2011;7(5):618-24
82. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334(5):292-5
83. Izadpanah A, Barnard RJ, Almeda AJ, et al. A Short-term Diet and Exercise Intervention Ameliorates Inflammation and Markers of Metabolic Health in Overweight/Obese Children. Am J Physiol Endocrinol Metab 2012;303(4):E542-50
84. Tandra S, Masters AR, Jones DR, et al. Effect of Roux-en-Y Gastric Bypass Surgery on the Metabolism of the Orally Administered Medications. Digestive Disease Week; Chicago, IL; 2011
85. Peters J, Oswald S, Haenisch S, et al. Influence of Roux-en-Y gastric bypass surgery on the disposition of paracetamol, talinolol and amoxicillin in obese patients. American Society of Clinical Pharmacology and Therapeutics-Annual Meeting; Dallas, USA; 2011
86. Wills SM, Zekman R, Bestul D, et al. Tamoxifen malabsorption after Roux-en-Y gastric bypass surgery: case series and review of the literature. Pharmacotherapy 2010;30(2):217
87. Park DM, Shah DD, Egorin MJ, Beumer JH. Disposition of temozolomide in a patient with glioblastoma multiforme after gastric bypass surgery. J Neurooncol 2009;93(2):279-83
88. Magee SR, Shih G, Hume A. Malabsorption of oral antibiotics in pregnancy after gastric bypass surgery. J Am Board Fam Med 2007;20(3):310-13
89. Pournaras DJ, Footitt D, Mahon D, Welbourn R. Reduced phenytoin levels in an epileptic patient following Roux-En-Y gastric bypass for obesity. Obes Surg 2011;21(5):684-5
90. Fuller AK, Tingle D, DeVane CL, et al. Haloperidol pharmacokinetics following gastric bypass surgery. J Clin Psychopharmacol 1986;6(6):376-8
91. Skottheim IB, Stormark K, Christensen H, et al. Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients. Clin Pharmacol Ther 2009;86(3):311-18
92. Padwal RS, Ben-Eltriki M, Wang X, et al. Effect of gastric bypass surgery on azithromycin oral bioavailability. J Antimicrob Chemother 2012;67(9):2203-6
93. Padwal RS, Gabr RQ, Sharma AM, et al. Effect of gastric bypass surgery on the absorption and bioavailability of metformin. Diabetes Care 2011;34(6):1295-300
94. Rogers CC, Alloway RR, Alexander JW, et al. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. Clin Transplant 2008;22(3):281-91
95. De Smet J, Colin P, De Paepe P, et al. Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery. J Antimicrob Chemother 2012;67(1):226-9
96. Rubio IG, Galrao AL, Santo MA, et al. Levothyroxine absorption in morbidly obese patients before and after Roux-En-Y gastric bypass (RYGB) surgery. Obes Surg 2012;22(2):253-8
97. Roerig JL, Steffen K, Zimmerman C, et al. Preliminary comparison of sertraline levels in postbariatric surgery patients versus matched nonsurgical cohort. Surg Obes Relat Dis 2012;8(1):62-6
98. Marterre WF, Hariharan S, First MR, Alexander JW. Gastric bypass in morbidly obese kidney transplant recipients. Clin Transplant 1996;10(5):414-19
99. Klockhoff H, Naslund I, Jones AW. Faster absorption of ethanol and higher peak concentration in women after gastric bypass surgery. Br J Clin Pharmacol 2002;54(6):587-91
100. Thummel KE, Shen DD. Appendix II. Design and optimization of dosage regimens: Pharmacokinetic data. In: Hardman JG, Limbard LE, Goodma-Gilman A, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 10th edition. McGraw-Hill; New York:2001
101. Maxon HR, Ritschel WA, Volle CP, et al. Pilot study on the absolute and relative bioavailability of Synthroid and Levothroid, two brands of sodium levothyroxine. Int J Clin Pharmacol Ther Toxicol 1983;21(8):379-82
102. Trausch B, Oertel R, Richter K, Gramatte T. Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man. Biopharm Drug Dispos 1995;16(5):403-14
103. Oswald S. (Poster) Influence of Roux-en-Y gastric bypass surgery on the disposition of paracetamol, talinolol and amoxicillin in obese patients. American Society of Clinical Pharmacology and Therapeutics-Annual Meeting; Dallas, USA; 2011
104. Hunziker ME, Suehs BT, Bettinger TL, Crismon ML. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther 2005;27(8):1126-43
105. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC. The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol 2007;3(5):741-53
106. Klaassen CD, Aleksunes LM. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev 2010;62(1):1-96
107. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011;50(2):81-98
108. Kusuhara H, Ito S, Kumagai Y, et al. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther 2011;89(6):837-44
109. Cho SK, Yoon JS, Lee MG, et al. Chung JY 2011. Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants. Clin Pharmacol Ther 2011;89(3):416-21
110. Lo A, Burckart GJ. P-glycoprotein and drug therapy in organ transplantation. J Clin Pharmacol 1999;39(10):995-1005
111. Maluenda F, Csendes A, De Aretxabala X, et al. Alcohol absorption modification after a laparoscopic sleeve gastrectomy due to obesity. Obes Surg 2010;20(6):744-8
112. Pavlovsky C, Egorin MJ, Shah DD, et al. Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia. Pharmacotherapy 2009;29(9):1152-6